Avanos and Siemens Forge Alliance to Reshape Outpatient Pain Care

ALPHARETTA, Ga. – January 20, 2026 – Avanos Medical, Inc. (NYSE: AVNS) and global medtech leader Siemens Healthineers have announced a strategic co-marketing agreement poised to significantly impact the landscape of interventional pain management. The collaboration will integrate Avanos's radiofrequency ablation (RFA) technologies with Siemens Healthineers' mobile C-arm imaging systems, creating a unified solution designed for the rapidly growing outpatient market.

This partnership directly addresses a fundamental shift in healthcare delivery, where complex medical procedures are increasingly moving from traditional hospital settings to more cost-effective and efficient Ambulatory Surgery Centers (ASCs). By combining their respective expertise, the two companies aim to provide a seamless ecosystem that enhances procedural accuracy, streamlines clinical workflows, and ultimately improves patient outcomes in pain management.

Riding the Wave of Outpatient Care

The alliance between Avanos and Siemens Healthineers is strategically timed to capitalize on the powerful currents reshaping the U.S. healthcare system. The migration of pain management procedures to outpatient facilities is not a fleeting trend but a structural evolution driven by a confluence of factors, including value-based care initiatives, technological advancements in minimally invasive techniques, and patient preference for more convenient treatment settings. The COVID-19 pandemic further accelerated this transition, as hospitals sought to offload procedures to manage capacity and reduce infection risks.

Market analysis underscores the momentum in this sector. The pain management devices market, which includes the RFA systems central to this partnership, is projected to grow at a robust compound annual growth rate (CAGR) of over 9.5% through 2030. This growth is fueled by an aging population, the rising prevalence of chronic pain conditions, and a critical need for effective alternatives to opioid-based therapies.

ASCs and interventional pain practices are at the forefront of this shift, but they require integrated, versatile, and cost-effective systems to manage the increasing volume and complexity of cases. The Avanos-Siemens Healthineers collaboration aims to fill this exact need, providing a comprehensive package that combines best-in-class imaging and therapeutic technology.

"At Avanos, we're continuously looking for smart, strategic ways to deliver greater value to our customers," said Dave Pacitti, Chief Executive Officer of Avanos Medical. "Collaborating with Siemens Healthineers combines our RFA expertise with leading imaging technology to help providers work smarter, improve procedural precision, and expand access to advanced pain management in the outpatient setting."

The Quest for Precision in Pain Management

At the heart of the collaboration is the synergy between two complementary technologies. Radiofrequency ablation is a minimally invasive procedure where a specialized needle-like probe delivers electrical current to heat and disrupt nerve tissue, thereby blocking pain signals. The success of this procedure is entirely dependent on the physician's ability to place the probe with millimeter accuracy.

This is where Siemens Healthineers' mobile C-arm systems, such as the Cios Select and Cios Flow, play a pivotal role. These devices provide high-resolution, real-time X-ray imaging, allowing clinicians to visualize anatomical structures and guide the RFA probe to its precise target. This integration of advanced imaging and therapy is critical for enhancing both the safety and efficacy of pain interventions.

By creating a seamless workflow, the combined solution promises to reduce procedure times, increase consistency, and improve the overall patient experience. For patients, this means more effective relief from chronic pain with reduced recovery times and a lower risk of complications. For providers, it means greater confidence and efficiency in the operating room.

"Our mobile c-arm systems are designed to improve clinical performance and simplify daily procedures," noted Christiana Gallagher, Head of Mobile C-Arms, North America, at Siemens Healthineers. Felicia Kurz, Head of Advanced Therapies, North America, at Siemens Healthineers, added, "This collaboration brings those benefits to more pain management settings, giving outpatient centers the tools to expand their capabilities, work efficiently, and provide exceptional care for their patients."

A Strategic Alliance in a Competitive Market

From a business perspective, the agreement represents a calculated strategic move for both companies. For Avanos Medical, the partnership leverages its strongest and fastest-growing segment. The company's RFA business has consistently reported double-digit growth, driven by its Coolief, AscendTech, and Trident product lines. Aligning with an imaging powerhouse like Siemens Healthineers provides a powerful endorsement and expanded sales channel, solidifying its position in the non-opioid pain solutions market.

For Siemens Healthineers, the collaboration offers a targeted pathway to deepen its penetration into the lucrative and expanding outpatient pain care sector. While its C-arm systems are already used in these settings, the formal partnership creates a differentiated, comprehensive offering that stands out in a competitive field that includes major players like GE Healthcare and Philips. The focus on an "integrated ecosystem" suggests a deeper collaboration on training, sales, and marketing than simply offering compatible standalone devices.

Initially targeting the U.S. market, the agreement will involve joint education programs, sales training, and marketing initiatives. The goal is to build awareness around the clinical and operational advantages of the integrated solution, creating a new standard for technology in interventional pain practices.

Navigating the Healthcare Landscape

The success of this venture will also depend on the broader regulatory and reimbursement environment, which currently appears favorable. A key driver for the adoption of technologies like RFA is the national effort to combat the opioid crisis. Government initiatives and legislation, such as the NOPAIN Act, are designed to encourage the use of non-opioid alternatives by improving reimbursement in outpatient settings like ASCs.

While the implementation of such policies can be gradual, the underlying trend provides a significant tailwind for the Avanos-Siemens Healthineers solution. Favorable reimbursement policies in North America are already a primary driver of the pain management device market. However, the regulatory pathway for fully integrated medical device systems is still an evolving area, and manufacturers must navigate existing frameworks that were largely designed for standalone products.

By entering the market with a strong, clinically-focused partnership, Avanos and Siemens Healthineers are well-positioned to navigate this landscape. Their combined solution not only meets a pressing clinical need but also aligns with the economic and policy forces that are fundamentally reshaping how and where patient care is delivered.